Personalized fMRI-Guided TMS Targeting the Threat Neurocircuitry in PTSD: A Randomized Clinical Trial
Sanne J.H. van Rooij·W M McDonald·Sean Minton·Cecilia A. Hinojosa·Joshua Lukemire·Rebecca Lipschutz·Rebecca Hinrichs·Natalie Merrill·Timothy D. Ely·Kristina Dahlgren·Patlapa Sompolpong·Gregory Job·Patricio Riva-posse·Paul E. Holtzheimer·Vince D. Calhoun·Joan A. Camprodon·Sheila A.M. Rauch·Nadine J. Kaslow·Kerry J. Ressler·Tanja Jovanovic·Ryan Langhinrichsen-Rohling
Transcranial magnetic stimulation (TMS) has shown promise in reducing posttraumatic stress disorder (PTSD) symptoms, with varied clinical results. A mechanistic understanding is needed to personalize treatment and improve response rates. The threat neurocircuitry, specifically the right amygdala, has consistently been implicated in PTSD pathophysiology. This neuroscience-informed trial aimed to modulate the threat neurocircuitry using functional MRI (fMRI)–guided TMS to treat PTSD.